🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children

Recruitingn/aAges 1 Year - 18 YearsAllThe First Affiliated Hospital of Xiamen University
NCT06530004 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This was a retrospective study. Children who were diagnosed with refractory nephrotic syndrome and treated with rituximab (RTX) and followed up for ≥1 year in the Department of Pediatrics, the First Affiliated Hospital of Xiamen University from March 2020 to March 2026 were enrolled. Personal information, past medical history, clinical examination data and follow-up data before and after the use of RTX were extracted from the medical record system. (1) The median relapse-free survival, the number of relapses and the adverse reactions of RTX were compared before and after RTX treatment, and the clinical efficacy and safety of RTX were evaluated. (2) By comparing the annual relapse frequency, reduction and withdrawal of steroids and immunosuppressive agents, B cell reconstitution and adverse drug reactions between prophylactic RTX and post-relapse RTX maintenance regimens; (3) Multivariate

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Children clinically diagnosed with FRNS/SDNS/SRNS with complete clinical data; * age \< 18 years old; * For the first time using RTX treatment, and used in nephrotic syndrome ease; * The follow-up for 1 year or more. Exclusion Criteria: * Congenital or infantile nephrotic syndrome, secondary nephrotic syndrome (such as lupus nephritis, IgA nephropathy, purpura nephritis, hepatitis B nephritis, etc.); * Active stage of hepatitis, complicated with severe infection, severe deficiency of immune response, malignant diseases; * Estimated glomerular filtration rate (GFR) \<60mL/min/1.73m2.
💊

What it tests

  • Rituximab
📍

Where

1 site
First affiliated hospital of xiamen university
Xiamen, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy